Status:
ACTIVE_NOT_RECRUITING
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
Lead Sponsor:
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators...
Eligibility Criteria
Inclusion
- 1）Age between 18 to 65 years old (inclusive), regardless of gender. 2) Meets diagnostic criteria for chronic hepatitis B (documented HBsAg positivity or HBV DNA positivity for more than 6 months, or confirmed by liver biopsy histopathology).
- 3)No prior treatment with any nucleos(t)ide analogue oral antiviral therapy; or, previous treatment with any nucleos(t)ide analogue must have ended at least 6 months prior to baseline.
- 4\) Any interferon therapy (both pegylated and non-pegylated) must be completed at least 1 year prior to baseline visit.
- 5\) Willing to use effective non-pharmacological contraception during the trial period.
Exclusion
- Hypersensitive to the study drug, its metabolites or any excipient in its formula;
- With previous or present clinical hepatic decompensation (e.g., ascites, hepatic encephalopathy or varicose vein haemorrhage)
- Complicated with liver diseases, including chronic alcoholic hepatitis, drug-induced hepatitis, etc.
- Complicated with HCV, HIV or HDV infections
- Documented resistance to the antiviral drug (Tenofovir).
- Any cardiovascular, hematologic,pulmonary or nervous diseases deemed serious by the investigator
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2030
Estimated Enrollment :
1444 Patients enrolled
Trial Details
Trial ID
NCT07203118
Start Date
July 1 2025
End Date
February 28 2030
Last Update
October 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Jilin University
Jilin, changchun, China